Hualan Biological Vaccine Inc. (SHE:301207)
China · Delayed Price · Currency is CNY 17.22
-0.48 (-2.71%)
Sep 11, 2026, 3:04 PM CST
Hualan Biological Vaccine Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 10,246 | 11,085 | 10,418 | 16,680 | 17,832 | - | |
Market Cap Growth | -6.06% | 6.40% | -37.54% | -6.46% | - | - |
Enterprise Value | 8,095 | 8,009 | 8,180 | 14,346 | 15,905 | - |
Last Close Price | 17.22 | 17.78 | 16.03 | 24.65 | 26.19 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 51.66 | 60.60 | 50.69 | 19.40 | 34.32 | - |
Forward PE | 47.83 | 7.75 | 9.86 | 15.22 | 17.00 | - |
PS Ratio | 8.63 | 9.22 | 9.24 | 6.92 | 9.77 | - |
PB Ratio | 1.95 | 1.94 | 1.73 | 2.66 | 3.24 | - |
P/TBV Ratio | 1.95 | 1.95 | 1.74 | 2.67 | 3.26 | - |
P/FCF Ratio | 25.28 | 31.91 | 25.02 | 20.21 | 90.98 | - |
P/OCF Ratio | 24.55 | 31.04 | 22.26 | 18.78 | 61.78 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.82 | 6.66 | 7.25 | 5.95 | 8.71 | - |
EV/EBITDA Ratio | 30.50 | 34.62 | 34.81 | 14.03 | 24.91 | - |
EV/EBIT Ratio | 65.29 | 88.73 | 86.43 | 16.27 | 31.55 | - |
EV/FCF Ratio | 19.97 | 23.05 | 19.64 | 17.38 | 81.14 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | - | - | 0.05 | 0.05 | 0.06 | 0.18 |
Debt / EBITDA Ratio | - | - | 1.28 | 0.29 | 0.47 | 0.68 |
Debt / FCF Ratio | - | - | 0.72 | 0.36 | 1.53 | - |
Net Debt / Equity Ratio | -0.41 | -0.49 | -0.49 | -0.37 | -0.34 | -0.16 |
Net Debt / EBITDA Ratio | -8.10 | -12.04 | -12.45 | -2.26 | -2.90 | -0.61 |
Net Debt / FCF Ratio | -5.31 | -8.02 | -7.03 | -2.80 | -9.43 | 6.82 |
Asset Turnover | 0.18 | 0.17 | 0.14 | 0.32 | 0.32 | 0.45 |
Inventory Turnover | 0.89 | 1.68 | 1.50 | 2.24 | 2.69 | 4.64 |
Quick Ratio | 3.07 | 3.70 | 3.19 | 2.73 | 2.57 | 1.43 |
Current Ratio | 4.42 | 3.92 | 3.40 | 3.10 | 2.73 | 1.51 |
Return on Equity (ROE) | 3.55% | 3.12% | 3.35% | 14.63% | 12.51% | 24.86% |
Return on Assets (ROA) | 1.18% | 0.78% | 0.76% | 7.32% | 5.43% | 10.28% |
Return on Invested Capital (ROIC) | 3.80% | 2.93% | 2.58% | 19.83% | 14.81% | 30.53% |
Return on Capital Employed (ROCE) | 2.30% | 1.60% | 1.60% | 14.00% | 9.10% | 23.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.94% | 1.65% | 1.97% | 5.16% | 2.91% | - |
FCF Yield | 3.96% | 3.13% | 4.00% | 4.95% | 1.10% | - |
Dividend Yield | 9.29% | 7.87% | 1.25% | 2.43% | 0.76% | - |
Payout Ratio | 443.98% | 277.66% | 162.67% | 13.95% | 17.49% | 2.06% |
Buyback Yield / Dilution | -0.11% | 0.51% | 0.71% | -2.03% | -9.33% | -0.01% |
Total Shareholder Return | 9.18% | 8.39% | 1.96% | 0.40% | -8.57% | -0.01% |